References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailClinical components linked to sarcopenia: the sarcophage study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Osteoporosis International (2015), 26(S1), 144

Detailed reference viewed: 48 (14 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of drugs to treat sarcopenia
Reginster, Jean-Yves ULg; Cooper, C; Rizzoli, R et al

in Osteoporosis International (2015), 26(S1), 62

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailCan we identify patients to be treated in osteoarthritis?
Arden, NK; Richette, P; Cooper, C et al

in Osteoporosis International (2015), 26(S1), 61-62

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailTrabecular bone score (TBS) as a new complementary appproach for osteoporosis evaluation in clinical practice
Harvey, NC; Binkley, N; Brandi, ML et al

in Osteoporosis International (2015), 26(S1), 60

Detailed reference viewed: 34 (1 ULg)
Full Text
Peer Reviewed
See detailCritical evaluation of promising markers for sarcopenia
CAVALIER, Etienne ULg; GADISSEUR, Romy ULg; GEBOES, Séverine ULg et al

in Osteoporosis International (2015), 26(S1), 49-50

Detailed reference viewed: 47 (10 ULg)
Full Text
Peer Reviewed
See detailThe position of Strontium ranelate in today's management of osteoporosis
Reginster, Jean-Yves ULg; Brandi, ML; Cannata-Andia, J et al

in Osteoporosis International (2015), 26(S1), 39

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension
Papapoulos, S; Roux, C; Bone, HG et al

in Osteoporosis International (2015), 26(S1), 37-39

Detailed reference viewed: 128 (3 ULg)
Full Text
Peer Reviewed
See detailOcanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2015), 26(S1), 35-36

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailThe clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Cianferotti, Luisella; Cricelli, Claudio; Kanis, John A. et al

in Endocrine (2015)

Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation. These metabolites ... [more ▼]

Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation. These metabolites display different chemical properties with respect to the parental or native vitamin D3, i.e., cholecalciferol, which has been, so far, the supplement most employed in the treatment of vitamin D inadequacy. Hydrophilic properties of vitamin D3 derivatives facilitate their intestinal absorption and their manageability in the case of intoxication because of the shorter half-life. Calcidiol is a more hydrophilic compound than parental vitamin D3. Active vitamin D analogs, capable of binding the vitamin D receptor evoking vitamin D-related biological effects, are mandatorily employed in hypoparathyroidism and kidney failure with impaired 1alpha-hydroxylation. They have been shown to increase BMD, supposedly ameliorating calcium absorption and/or directly affecting bone cells, although their use in these conditions is jeopardized by the development of hypercalciuria and mild hypercalcemia. Further studies are needed to assess their overall safety and effectiveness in the long-term and new intermittent regimens, especially when combined with the most effective antifracture agents. [less ▲]

Detailed reference viewed: 25 (7 ULg)
Full Text
Peer Reviewed
See detailClinical components linked to sarcopenia: the sarcophage study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Journal of Frailty & Aging (2015), 4(S1), 89

Detailed reference viewed: 38 (6 ULg)
Full Text
Peer Reviewed
See detailMuscle fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Bautmans, I et al

in Journal of Frailty & Aging (2015), 4(S1), 61-62

Detailed reference viewed: 28 (11 ULg)
Full Text
Peer Reviewed
See detailHealth related quality of life in sarcopenia
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Journal of Frailty & Aging (2015), 4(S1), 61

Detailed reference viewed: 32 (6 ULg)
Full Text
Peer Reviewed
See detailPrevalence of frailty in nursing home residents according to various diagnostic tools
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Dardenne, Nadia ULg et al

in Journal of Frailty & Aging (2015), 4(S1), 61

Detailed reference viewed: 39 (3 ULg)
Full Text
Peer Reviewed
See detailRecommendation for the management of knee osteoarthritis
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg

in Bone, Muscle and Joint Diseases (2015), (S35), 40

Detailed reference viewed: 20 (8 ULg)
Full Text
Peer Reviewed
See detailA 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial.
Langdahl, Bente L.; Teglbjaerg, Christence S.; Ho, Pei-Ran et al

in The Journal of clinical endocrinology and metabolism (2015), 100(4), 1335-1342

Context: One in 4 men in the US aged >50 will suffer an osteoporosis-related fracture. Less data are available on osteoporosis treatment in men than women. Objective: Evaluate denosumab therapy in men ... [more ▼]

Context: One in 4 men in the US aged >50 will suffer an osteoporosis-related fracture. Less data are available on osteoporosis treatment in men than women. Objective: Evaluate denosumab therapy in men with low BMD. Design: Phase 3 study with two treatment periods: a previously reported 12-month double-blind, placebo-controlled phase and a 12-month open-label phase. Setting: Multicenter in North America and Europe. Participants: 228 men entered the open-label phase and 219 completed the study. Intervention: Men from the original denosumab (long-term) and placebo (crossover) groups received denosumab 60 mg SC every 6 months. Main Outcome Measures: BMD, serum C-telopeptide (sCTX), and safety. Results: During the open-label phase, continued BMD increases occurred with long-term denosumab treatment (2.2% lumbar spine; 0.9% total hip; 1.3% femoral neck; 1.3% trochanter; and 0.2% 1/3 radius), resulting in cumulative 24-month gains from baseline of 8.0%, 3.4%, 3.4%, 4.6%, and 0.7%, respectively (all P<0.01). The crossover group showed BMD gains after 12 months of denosumab treatment similar to the long-term denosumab group during the first treatment year. Significant reductions in sCTX were observed following denosumab administration. Adverse events rates were similar between groups and no new safety signals identified. Conclusions: In men with low BMD, denosumab treatment for a second year continued to increase BMD, maintained reductions in bone resorption, and was well tolerated. BMD increased in men initiating denosumab during the second year. These effects were similar to those previously seen in postmenopausal women with osteoporosis and men with prostate cancer on androgen deprivation therapy. [less ▲]

Detailed reference viewed: 43 (6 ULg)